TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16194311

Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (glycine) (0.5 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 120
Study: 12668699

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day)
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study: 10531848

Group type: EXPERIMENTAL
Intervention: Culturally competent diabetes education intervention
Number of subjects: 0
Study: 8705743

Group type: EXPERIMENTAL
Intervention: Argon laser iridotomy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sequential argon laser and Nd:YAG laser iridotomy
Number of subjects: 17
Study: 1679736

Group type: EXPERIMENTAL
Intervention: Enteral nutrition with a liquid oligopeptide diet (n = 55)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Combination of 6‐methylprednisolone (48 mg daily, tapered) and sulfasalazine (3 g daily) (n = 52)
Number of subjects: 107
Study: 6134042

Group type: EXPERIMENTAL
Intervention: Oral bromocriptine (1.25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3542346

Group type: EXPERIMENTAL
Intervention: Single dose of moxalactam 2 g intramuscularly
Number of subjects: 78

Group type: COMPARATOR
Intervention: Three-dose regimen of cefoxitin (2 g intramuscularly on call, followed by 2 g intravenously every six hours for two additional doses)
Number of subjects: 78
Study: 28481758

Group type: EXPERIMENTAL
Intervention: Adolescents (BOQ11-18)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Young Adults (YABOQ 18-30)
Number of subjects: 501
Study: 28393570

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 25774090

Group type: EXPERIMENTAL
Intervention: Sufentanil target-controlled infusion (TCI) at 0.1682 ng/ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil target-controlled infusion (TCI) at various concentrations (0.19, 0.1809, 0.1723, 0.1641, 0.1563, 0.1489 ng/ml)
Number of subjects: 60
Study: 23062248

Group type: EXPERIMENTAL
Intervention: Massage (twice-daily for 4 weeks by licensed massage therapists)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control care (twice-daily for 4 weeks)
Number of subjects: 44
Study: 20628648

Group type: EXPERIMENTAL
Intervention: Left-moving events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right-moving events
Number of subjects: 0
Study: 18258511

Group type: EXPERIMENTAL
Intervention: SHOP-89 (1989-1993)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: SHOP-94 (1994-1998)
Number of subjects: 673
Study: 16613928

Group type: EXPERIMENTAL
Intervention: i.v. acetaminophen 15 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: i.m. meperidine 1 mg kg(‐1)
Number of subjects: 80
Study: 14526483

Group type: EXPERIMENTAL
Intervention: Workers exposed to metallic mercury vapours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 10933330

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Oral propafenone
Number of subjects: 97
Study: 8625373

Group type: EXPERIMENTAL
Intervention: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks + oral collagen hydrolysate, 10 g per day for 24 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Oral collagen hydrolysate, 10 g per day for 24 weeks (after calcitonin treatment)
Number of subjects: 108
Study: 1351547

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (8 mmol over 5 min followed by 65 mmol over 24 h)
Number of subjects: 2316

Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 2316
Study: 2870810

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus Bevantolol 400 mg/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Dual therapy (Hydrochlorothiazide + Bevantolol)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 244
Study: 31045433

Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum during exercise
Number of subjects: 22
Study: 29595563

Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation
Number of subjects: 83

Group type: COMPARATOR
Intervention: Facemask noninvasive ventilation
Number of subjects: 83

Group type: COMPARATOR
Intervention: ICU-acquired weakness
Number of subjects: 83
Study: 26111953

Group type: EXPERIMENTAL
Intervention: EGFRI treatment
Number of subjects: 85
Study: 25653802

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment for 20 sessions of 20 minutes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (same instrument but off)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment
Number of subjects: 120
Study: 22634184

Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg QD + Open-label optimized background therapy (OBT)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Vicriviroc 30 mg QD + OBT
Number of subjects: 857

Group type: COMPARATOR
Intervention: Placebo + Open-label optimized background therapy (OBT)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Placebo + OBT
Number of subjects: 857
Study: 19907299

Group type: EXPERIMENTAL
Intervention: 20-G standard PPV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 25-G transconjunctival sutureless vitrectomy (TSV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between 20-G and 25-G groups
Number of subjects: 60
Study: 18631166

Group type: EXPERIMENTAL
Intervention: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 7 weeks of storage
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 11 weeks of storage
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aerobic storage
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acidic or neutral AS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neutral or basic pH AS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cold rejuvenation during anaerobic storage
Number of subjects: 8
Study: 16144170

Group type: EXPERIMENTAL
Intervention: Intraventricular administration of rt-PA (3 mg every 24 hours)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intraventricular administration of rt-PA
Number of subjects: 21
Study: 12361993

Group type: EXPERIMENTAL
Intervention: Lumbar support used daily for the first week and on LBP days for the following 6 months
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lumbar support
Number of subjects: 59
Study: 10462164

Group type: EXPERIMENTAL
Intervention: Spinal flexibility-plus-aerobic exercise
Number of subjects: 210

Group type: COMPARATOR
Intervention: Aerobic-only exercise
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 210
Study: 7892144

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube
Number of subjects: 18

Group type: COMPARATOR
Intervention: No NG tube
Number of subjects: 18
Study: 2623306

Group type: EXPERIMENTAL
Intervention: Oxyntic cell vagotomy with simple closure
Number of subjects: 180

Group type: COMPARATOR
Intervention: Simple closure alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study: 356240

Group type: EXPERIMENTAL
Intervention: Proquazone (3x300 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Naproxen (2x250 mg plus one placebo capsule/day)
Number of subjects: 36
Study: 30428474

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg bid for 3 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg bid combined with lactulose 30-60 mL daily for 3 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rifaximin therapy with and without lactulose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rifaximin therapy
Number of subjects: 5
Study: 30218387

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite (HDM) allergen extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26358331

Group type: EXPERIMENTAL
Intervention: Cold forceps polypectomy (CFP) with narrow-band imaging (NBI) evaluation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cold forceps polypectomy (CFP) with NBI evaluation
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cold forceps polypectomy (CFP)
Number of subjects: 146
Study: 24421304

Group type: EXPERIMENTAL
Intervention: Pragmatic exercise intervention (EXIMS) with usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 120
Study: 23295594

Group type: EXPERIMENTAL
Intervention: Brazilian Cardioprotective Diet Program (weekly sessions with dietitians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual dietary therapy (Group B - weekly sessions with dietitian)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual dietary therapy (Group C - monthly sessions with dietitian)
Number of subjects: 0
Study: 19531257

Group type: EXPERIMENTAL
Intervention: Whole-meal rye bread (150 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: White wheat bread (150 g)
Number of subjects: 10
Study: 17218551

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 208
Study: 15538680

Group type: EXPERIMENTAL
Intervention: Prefabricated neoprene splint (PFN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Custom-made thermoplastic short opponens splint (CMT)
Number of subjects: 25
Study: 11808763

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 0.19 mg of CPP-ACP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 10.0 mg of CPP-ACP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 18.8 mg of CPP-ACP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum containing 56.4 mg of CPP-ACP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control gum (sorbitol- or xylitol-based without CPP-ACP)
Number of subjects: 30
Study: 9777110

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 7832578

Group type: COMPARATOR
Intervention: 0 g elemental calcium (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 g elemental calcium
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 g elemental calcium
Number of subjects: 24
Study: 3683094

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, sublingual)
Number of subjects: 6
Study: 29731413

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Finasteride and Placebo
Number of subjects: 2700
Study: 27172664

Group type: EXPERIMENTAL
Intervention: Skin wound induction gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 48
Study: 25083559

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Local Muscle Vibration (LMV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 21607791

Group type: EXPERIMENTAL
Intervention: Clavicle Score (CS)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (45 healthy volunteers)
Number of subjects: 172
Study: 20950433

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 104
Study: 18058457

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 110

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 110
Study: 15679765

Group type: EXPERIMENTAL
Intervention: Wireless pH capsule
Number of subjects: 50
Study: 11864667

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with induction late in labor (greater than or equal to 6 cm)
Number of subjects: 1862

Group type: COMPARATOR
Intervention: Continuous epidural analgesia with induction between 3 and 5 cm
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with an interval of greater than or equal to 360 minutes between induction and full dilatation
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Women with height less than 160 cm
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Women with prepregnancy weight greater than 65 kg
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Women aged greater than or equal to 35 years
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Women with gestational age greater than or equal to 41 weeks
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Fetal station above +2 at full dilatation
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Posterior fetal position
Number of subjects: 1862
Study: 7717486

Group type: EXPERIMENTAL
Intervention: Pethidine (0.85 mg.kg‐1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.7 micrograms.kg‐1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lignocaine (1 mg.kg‐1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 52
Study: 1972833

Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B phototherapy (Philips TL‐01)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PUVA photochemotherapy (oral 8‐MOP followed by UV‐A from Philips TL‐09)
Number of subjects: 10
Study: 381921

Group type: EXPERIMENTAL
Intervention: Piadar lotion, applied 2 to 3 times daily for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tolnaftate solution, applied 2 to 3 times daily for four weeks
Number of subjects: 20
Study: 31912799

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab (FOLFIRI/Cet)
Number of subjects: 199
Study: 31196899

Group type: EXPERIMENTAL
Intervention: Peppermint-flavoured chewing gum for 15 minutes
Number of subjects: 272

Group type: COMPARATOR
Intervention: 4 mg intravenous ondansetron
Number of subjects: 272
Study: 28777421

Group type: EXPERIMENTAL
Intervention: RG‐IV (retractable guidewire IV catheter)
Number of subjects: 218

Group type: COMPARATOR
Intervention: C‐IV (conventional IV catheter)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RG‐IV
Number of subjects: 218

Group type: COMPARATOR
Intervention: C‐IV
Number of subjects: 218
Study: 28956529

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (1 mg/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lipid microspheres loaded with flurbiprofen
Number of subjects: 72
Study: 24092829

Group type: EXPERIMENTAL
Intervention: High-phosphate diet (1800 mg/d) for 6 days
Number of subjects: 26
Study: 21843970

Group type: EXPERIMENTAL
Intervention: LH < P25
Number of subjects: 1764

Group type: COMPARATOR
Intervention: LH ≥ P25
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: LH > P75
Number of subjects: 1764

Group type: COMPARATOR
Intervention: LH ≤ P75
Number of subjects: 1764
Study: 19307106

Group type: EXPERIMENTAL
Intervention: AZI-ER 2g
Number of subjects: 71

Group type: COMPARATOR
Intervention: AZI-IR 500 mg
Number of subjects: 71
Study: 17702589

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion starting in the operating theatre (Group OT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Levosimendan infusion starting in the ICU (Group ICU)
Number of subjects: 45
Study: 15080773

Group type: EXPERIMENTAL
Intervention: 1 microg/kg ghrelin (acylated form)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 microg/kg ghrelin (acylated form)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (mannitol)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ghrelin administration (both doses)
Number of subjects: 18
Study: 11343562

Group type: EXPERIMENTAL
Intervention: Continuous infusion of milrinone (5 microg/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment without milrinone
Number of subjects: 20
Study: 9806580

Group type: EXPERIMENTAL
Intervention: Beta2 glycoprotein I IgM antibody and antinuclear antibody
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Autoantibodies
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Seropositivity for autoantibodies tested
Number of subjects: 360
Study: 7853124

Group type: COMPARATOR
Intervention: Toothbrushing alone (brush)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Toothbrushing plus chlorhexidine 0.12% rinse 2x/day (CHX)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Toothbrushing plus water irrigation 1x/day (irr+H2O)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Toothbrushing plus chlorhexidine 0.04% irrigation 1x/day (irr+CHX)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Irrigation groups (irr+H2O and irr+CHX)
Number of subjects: 125
Study: 2527829

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study: 1096388

Group type: EXPERIMENTAL
Intervention: Once-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E1R1)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Twice-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E2R2)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Initial inpatient phase of rifampicin 600 mg and ethambutol 25 mg/kg daily for 12 weeks
Number of subjects: 247
Study: 31661663

Group type: EXPERIMENTAL
Intervention: Traditional reduced‐exertion, high‐intensity interval training (TREHIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shortened‐sprint REHIT (SSREHIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sprint continuous training (SCT)
Number of subjects: 36
Study: 31237610

Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 28051986

Group type: EXPERIMENTAL
Intervention: Wavefront-Guided (WFG) PRK
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wavefront-Optimized (WFO) PRK
Number of subjects: 54
Study: 26562379

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wound Gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care plus Wound Gel (SOC + gel)
Number of subjects: 0
Study: 24289208

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1553
Study: 21111078

Group type: EXPERIMENTAL
Intervention: Escalating dose teriparatide (20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Constant dose teriparatide (30 μg daily for 18 months)
Number of subjects: 52
Study: 19224196

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1963

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1963

Group type: COMPARATOR
Intervention: Normal glucose tolerance
Number of subjects: 1963
Study: 16273395

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication on
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication off
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bilateral subthalamic nucleus (STN) stimulation off with low medication (usual dose)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bilateral subthalamic nucleus (STN) stimulation off with high medication (suprathreshold dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation on with low medication (usual dose)
Number of subjects: 39
Study: 15270795

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study: 11390722

Group type: EXPERIMENTAL
Intervention: HF1 (on-line predilution haemofiltration)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HF2 (as phase I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HD (high-flux haemodialysis)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HF (both HF1 and HF2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HF2
Number of subjects: 24
Study: 9497707

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 12
Study: 8088206

Group type: EXPERIMENTAL
Intervention: Portal infusion with Mitomycin‐C (MMC) and 5‐Fluorouracil (5‐FU) starting immediately after operation
Number of subjects: 533

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 533
Study: 11039044

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.5% zinc citrate and 0.2% Triclosan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 39
Study: 30826617

Group type: EXPERIMENTAL
Intervention: Spark-ignition emissions (GAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diesel (DIE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Road dust (RD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual oil (RO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary nitrate (SN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary sulfate PM2.5 (SS)
Number of subjects: 0
Study: 28643265

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 1479
Study: 26114379

Group type: EXPERIMENTAL
Intervention: Delayed-release (DR) prednisone
Number of subjects: 110
Study: 23241006

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Light-emitting diode (LED) placebo
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 21980964

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of lisinopril 10 mg and diclofenac sodium 100 mg
Number of subjects: 0